ClinicalTrials.gg
CompletedNCT05409430ANAISUpdated Jul 20, 2023

ANAIS Study to Confirm the Safety and Performance of the ANA 5F Advanced Neurovascular Access®

An interventional study of Neurothrombectomy in Acute Ischemic Stroke, sponsored by Anaconda Biomed S.L.. Completed at 3 sites in Spain. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-07-20.

Sponsored by Anaconda Biomed S.L. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 137 studies in Ischemic Stroke with a site in Spain — 37 open to participants now, 46 under way, 7 of them phase 3. Ischemic Stroke · Spain.

Enrollment
86th of 97
43 · median 240
Started
2022
with 12 others
No phase
48 of 137
15 open now
Registered
82nd of 137
by date
Lead sponsor
4 of 137
Anaconda Biomed S.L.

Among the 137 studies in Ischemic Stroke with a site in Spain, this one is the 86th largest by enrollment of the 97 interventional ones that give a count, is one of 13 that started in 2022, is one of 48 with no phase, and was the 82nd registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

37 of the 137 studies in Ischemic Stroke with a site in Spain are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 137 studies in Ischemic Stroke with a site in Spain, or all of them as a file.
02

Study summary

Prospective, single-arm, multi-center study to assess the safety and performance of the ANA 5F Advanced Neurovascular Access®, in combination with a stent retriever in patients with acute ischemic stroke.

Read the detailed description

ANA 5F Advanced Neurovascular Access®: distal access catheter system designed to assist in neurovascular procedures by facilitating the insertion and guidance of other devices (i.e. retrieval devices and intravascular catheters) and temporarily restricting blood flow at the target position.

The objective of this study is to confirm the safety and performance of the ANA 5F device to be used as a tool to facilitate the Solitaire stent retriever placement and provide temporary restriction of blood flow in stroke patients undergoing neurothrombectomy for an acute large vessel occlusion (LVO) treated 24 hours from symptom onset (last time the subject was seen well).

Population: Up to 30 Participants with Acute Ischemic Stroke (AIS), indicated for treatment with ANA 5F device in combination with Solitaire stent retriever, whose stroke is attributable to an occlusion of a large artery in the neurovasculature.

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

Keywords

  • AIS
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical

    1. Age ≥18 and ≤85 years.
    2. obtained from subject or acceptable subject surrogate (i.e. next of kin, or legal representative).
    3. A new focal disabling neurologic deficit consistent with acute cerebral ischemia.
    4. Baseline NIHSS obtained prior to procedure ≥ 8 points and ≤ 25 points.
    5. Pre-ictal mRS score of 0 or 1.
    6. Treatable as soon as possible and at least within 24 hours of symptom onset, defined as point in time when the subject was last seen well (at baseline) (Treatment start is defined as access puncture).
    7. Subjects being either (1) eligible for, and received, IV tPA/TNK within 3 hours of symptom onset or (2) ineligible for IV tPA/TNK treatment.

      Neuro Imaging

    8. Occlusion (TICI 0 or TICI 1 flow), of the terminal internal carotid artery, M1 or M2 segments of the middle cerebral artery, suitable for mechanical embolectomy, confirmed on conventional angiography.
    9. For patients treated ≤ 6 hours:

      1. MRI criterion: volume of diffusion restriction visually assessed ≤50 mL

        OR

      2. CT criterion: Alberta Stroke program early CT score (ASPECTS) 6 to 10 on baseline CT.

      For patients treated 6 to 24 hours. Target Mismatch Profile on CT perfusion or MRI (ischemic core volume is \< 70 ml, mismatch ratio is > 1.8 and mismatch volume is > 15 ml)

    10. The subject is indicated for neurothrombectomy treatment with SOLITAIRE, by the Interventionalist.

Exclusion criteria

Exclusion Criteria:

  • Clinical

    1. Initially treated with a different thrombectomy device.
    2. Subject has suffered a stroke in the past 1 year.
    3. Occlusion (TICI 0 or TICI 1 flow) of the basilar or vertebral arteries.
    4. Clinical symptoms suggestive of bilateral stroke or stroke in multiple territories.
    5. Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with antivitamin K, with >3.0.
    6. Known baseline glucose of \<50 mg/dL or >400 mg/dL.
    7. Severe, sustained hypertension (systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg).
    8. Serious, advanced, or terminal illness with anticipated of less than 1 year.
    9. History of life-threatening allergy (more than rash) to contrast medium.
    10. Known renal insufficiency with creatinine ≥3 mg/dL or (GFR) \<30 mL/min.
    11. Cerebral vasculitis.
    12. Subject is a current user or has a recent history of cocaine use.
    13. Pregnant and/or lactating woman.
    14. Patient participating in a study involving an drug or device that would impact this study.
    15. Patients that are unlikely to be available for a 90-day follow-up (e.g. no fixed home address, visitor from overseas).

      Neuro Imaging

    16. CT or MRI evidence of hemorrhage (the presence of microbleeds is allowed).
    17. Angiographic evidence of vasculitis.
    18. Significant mass effect with midline shift.
    19. Evidence of complete occlusion, high grade stenosis or arterial dissection in the extracranial or internal carotid artery (ICA).
    20. Subjects with known or suspected underlying intracranial atherosclerotic lesions responsible for the target occlusion.
    21. Subjects with occlusions in multiple vascular territories (e.g., bilateral anterior circulation, or anterior/posterior circulation).
    22. Evidence of intracranial tumor.
    23. Suspicion of aortic dissection presumed septic embolus, or suspicion of bacterial endocarditis.
    24. Severe arterial tortuosity likely to prevent stable positioning of the guide catheter in the distal cervical segment (C1) or petrous segment (C2) of internal carotid artery (ICA).

      Technical

    25. Inability to create an arterial access and / or to advance a guide catheter due to anatomical or physiological restrictions (i.e. vasospasm).
    26. Inability of the guide catheter to obtain a stable position in the ICA.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Patients with Acute Ischemic Stroke (AIS)

    Patients with Acute Ischemic Stroke (AIS), indicated for treatment with ANA 5F device in combination with Solitaire stent retriever, whose stroke is attributable to an occlusion of a large artery in the neurovasculature.

    Device: Neurothrombectomy

Interventions

  • DeviceNeurothrombectomy

    The ANA 5F device is intended to be inserted, be navigated to the neurovascular anatomy inside an outer catheter and be used as a conduit for insertion and guidance of intravascular catheters and retrieval devices into a selected blood vessel. The funnel is deployed by retracting the conduit catheter and is intended, when deployed, to provide temporary vascular flow restriction. The device is indicated for the introduction of interventional devices into the neuro vasculature, during interventions for restoring blood flow in patients experiencing acute ischemic stroke due to large vessel occlusion.

    Also known as: Mechanical thrombectomy (MT)

06

What researchers measure

Primary outcomes

  1. Successful reperfusion, defined as rate of patients achieving mTICI ≥2b.

    Successful reperfusion, defined as rate of patients achieving mTICI ≥2b in the target vessel within three passes of the ANA 5F before the use of rescue therapy, assessed by the Core Lab.

    Time frame: Day0. Intraoperative

  2. The composite of symptomatic Intracranial Hemorrhage (sICH) within 24 hours (-8 / +12 h) post-procedure, together with serious adverse device effects.

    The composite of symptomatic Intracranial Hemorrhage (sICH) within 24 hours (-8 / +12 h) post-procedure, together with serious adverse device effects (excluding those already counted in sICH) at Day 5 (± 12 h) or discharge (whatever comes first).

    Time frame: 24 hours (-8 / +12 h) post-procedure

Secondary outcomes

  1. Occurrence of Intracranial Hemorrhage (ICH); any symptomatic or asymptomatic ICH

    Time frame: 90 days

Other outcomes

  1. Rate of subjects with a neurological deterioration of ≥4 points on NIHSS

    Time frame: 24 hours

  2. Occurrence of embolization in a previously uninvolved territory on the cerebral angiogram.

    Time frame: Day 0. Intraoperative

  3. Procedure-related mortality rate.

    Time frame: Day 5 (± 12 hours) or discharge, whichever comes first, and at 90 days.

07

Study locations

3 sites
  • Hospital Universitari de la Vall d'Hebron
    Barcelona, Spain
  • Hospital Universitari Dr. Josep Trueta
    Girona, Spain
  • Hospital Clínico Universitario Virgen de la Arrixaca
    Murcia, Spain
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Jul 2023, 14 months.

Of 80 industry-sponsored interventional studies with no phase under Ischemic Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's 14 months is below that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2022
First posted
Jun 8, 2022
StartActual
May 9, 2022
Primary completionActual
Jul 10, 2023
CompletionActual
Jul 10, 2023
Last update
Jul 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05409430
Lead sponsor
Anaconda Biomed S.L.
Responsible party
Sponsor
First posted
Jun 8, 2022
Start date
May 9, 2022
Primary completion
Jul 10, 2023
Completion
Jul 10, 2023
Last update
Jul 20, 2023

Study contacts

René Spaargaren, MD
study chair · Anaconda Biomed S.L.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion